ThyroSeqV3® provides clear results for management of thyroid nodules and cancer
High diagnostic accuracy
High reduction (61-67%) of diagnostic surgeries in nodules with indeterminate cytology
Probability of cancer and prediction of cancer recurrence, informing personalized patient management
Flexibility in acceptable sample types
THYROSEQV3® UTILITY FOR PROGNOSTICATION AND THERAPY
Comprehensive molecular profiling by ThyroSeq provides preoperative prognostication of cancerous nodules, informing the extent of surgery and therapeutic options
ThyroSeqV3® provides:
Preoperative assessment of the Risk of Cancer Recurrence (RCR)
Detection of clinically actionable therapeutic targets
Diagnostic Utility
The primary application of ThyroSeqV3® is to provide accurate cancer diagnosis in thyroid nodules with indeterminate FNA cytology
Uncertain risk of cancer in thyroid nodules with indeterminate FNA cytology (Bethesda categories III, IV, and V) hampers clinical management of these patients. ThyroSeqV3® stratifies these nodules into those that are likely benign and may be observed and those that are likely malignant and require surgical management. For the latter nodules, ThyroSeqV3® may inform the extent of surgical management (lobectomy vs. total thyroidectomy).
In addition, ThyroSeqV3® may help to clarify diagnosis in benign cytology nodules (Bethesda II) with clinical suspicion for malignancy.
Patient Management
ThyroSeqV3® test results refine cancer probability in thyroid nodules with indeterminate cytology, informing the most appropriate management of these patients.
News & Press Releases
ThyroSeq® GC
ThyroSeq® Genomic Classifier (GC) test utilizes next-generation sequencing to analyze DNA and RNA of 112 thyroid-related genes for four main classes of molecular alterations, including mutations, gene fusions, copy number alterations, and gene expression alterations The results are processed by a unique Genomic Classifier (GC) and reported as Positive or Negative1
ThyroSeq can help determine if surgery is needed
ThyroSeq testing can safely prevent unnecessary diagnostic surgery in the majority of patients with thyroid nodules with indeterminate (Bethesda III or IV) cytology. When ThyroSeq results are negative for these nodules, the probability of cancer is similar to that of a benign cytology diagnosis.
ThyroSeq provides prognostic information about cancer
If ThyroSeq results are positive, the test provides additional information about the nodule to help you and your doctor decide your individualized plan, which in some cases may include preserving part of your thyroid and protecting your natural thyroid function.